Literature DB >> 26686866

Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.

Kamrouz Ghadimi1, Keith E Dombrowski2, Jerrold H Levy1, Ian J Welsby1.   

Abstract

Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin:LMWH complex but does not trigger prothrombotic activity. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) was able to dose-dependently reverse Factor Xa inhibition and restore thrombin generation for the duration of drug administration. Further trials are underway to examine its safety and efficacy in the population of patients experiencing FXa inhibitor-related bleeding.

Entities:  

Keywords:  Andexanet alfa; Apixaban; Factor Xa inhibitors; Hemostasis; Morpholines; Prothrombinase; Rivaroxaban; Thiophenes; Thrombin Generation; Thrombosis

Mesh：

Substances：

Year:  2016        PMID： 26686866     DOI： 10.1586/17474086.2016.1135046

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN： 1747-4094            Impact factor:   2.929


  19 in total

1.  Paroxysmal Atrial Fibrillation in a Patient on Hemodialysis.

Authors:  Charmaine E Lok
Journal:  Clin J Am Soc Nephrol       Date:  2017-06-09       Impact factor: 8.237

Review 2.  Biological Products: Cellular Therapy and FDA Approved Products.

Authors:  Ali Golchin; Tahereh Zarnoosheh Farahany
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

3.  Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Mark Crowther; John W Eikelboom; C Michael Gibson; John T Curnutte; John H Lawrence; Patrick Yue; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Andrew M Demchuk; Daniel J Pallin; Mauricio Concha; Shelly Goodman; Janet Leeds; Sonia Souza; Deborah M Siegal; Elena Zotova; Brandi Meeks; Sadia Ahmad; Juliet Nakamya; Truman J Milling
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

4.  The scope and value of an anticoagulation stewardship program at a community teaching hospital.

Authors:  Maura K Wychowski; Christina I Ruscio; Peter A Kouides; Ronald L Sham
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

Review 5.  Recent major advances in cardiovascular pharmacotherapy.

Authors:  James Milner; Andreia Cunha; Carlota Gamboa-Cruz; Julie Reis; Márcia Campos; Natália António
Journal:  Eur J Clin Pharmacol       Date:  2018-03-27       Impact factor: 2.953

Review 6.  Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.

Authors:  Kamrouz Ghadimi; Jerrold H Levy; Ian J Welsby
Journal:  Anesth Analg       Date:  2016-05       Impact factor: 5.108

7.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

Review 8.  Perioperative management of the bleeding patient.

Authors:  K Ghadimi; J H Levy; I J Welsby
Journal:  Br J Anaesth       Date:  2016-12       Impact factor: 9.166

Review 9.  Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

Authors:  Michelangelo Sartori; Benilde Cosmi
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

Review 10.  Apixaban to prevent stroke in patients with atrial fibrillation: a review.

Authors:  Benjamin E Peterson; Sana M Al-Khatib; Christopher B Granger
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.